|Bid||253.88 x 100|
|Ask||254.03 x 100|
|Day's Range||253.47 - 256.35|
|52 Week Range||184.50 - 260.24|
|PE Ratio (TTM)||7.93|
|Dividend & Yield||2.80 (1.10%)|
|1y Target Est||N/A|
Sen. Claire McCaskill asked four more drug companies and three distributors to provide documents and explain steps they have taken to stop prescription painkillers from being diverted to the black market....
Here's the call.
Shares of Valeant Pharmaceuticals International (VRX) are climbing Monday after the drug maker announced the $190 million sale of Obagi Medical Products to Shonghua Finance Acquisition Fund. The deal is the latest asset sale by the beleaguered drug maker as it labors to meet its goal of $5 billion in debt reduction by February 2018. The company has shed its iNova division, as well as cancer treatment maker Dendreon, and sold some skin care lines to L’Oreal, and is throwing the proceeds at its debt load.